Physician profile
Benjamin Williams
NPI 1013195395
$2,919.40
in general payments reported to CMS, 2019-2025
34 companies · $835 in 2025
The $835 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.77 · 2021: $96.12 · 2022: $450 · 2023: $735 · 2024: $750 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $478.78 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $430.37 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $286.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $225.44 | 2021-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $156.47 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.06 | 2023-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $109.01 | 2025 | Gemtesa |
| Amgen INC. | $101.01 | 2023-2025 | Repatha, Repatha, Otezla |
| Exact Sciences Corporation | $92.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $85.51 | 2022-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $83.50 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $68.23 | 2023-2025 | Voquezna |
| Supernus Pharmaceuticals, INC. | $66.68 | 2023-2024 | Qelbree, Qelbree |
| Dexcom, INC. | $52.69 | 2024-2025 | Dexcom G6 Transmitter |
| Noven Therapeutics, LLC | $47.92 | 2023 | Xelstrym, Secuado |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $45.23 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $44.73 | 2024 | Rexulti |
| Abbvie INC. | $39.04 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $35.72 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $34.05 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.76 | 2022 | |
| Collegium Pharmaceutical, INC. | $31.68 | 2019-2025 | Jornay Pm |
| Biocryst US Sales Co., LLC | $30.13 | 2024 | Orladeyo |
| Acadia Pharmaceuticals INC | $26.52 | 2025 | Daybue |
| Lundbeck LLC | $22.09 | 2024 | Rexulti |
| Antares Pharma, INC. | $21.52 | 2023 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $21.15 | 2023 | |
| Corium, LLC | $20.02 | 2024 | Azstarys |
| Saluda Medical Americas, INC. | $19.33 | 2024 | Evoke |
| Novartis Pharmaceuticals Corporation | $18.58 | 2022 | |
| Shield Therapeutics INC | $17.88 | 2024 | |
| Amarin Pharma, INC. | $17.37 | 2022 | |
| Tris Pharma INC | $16.48 | 2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $15.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.